Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D4MZR2
|
|||
| Drug Name |
BPM 31510
|
|||
| Drug Type |
Lipid-drug conjugate
|
|||
| Indication | Glioma [ICD-11: 2A00.0] | Phase 2 | [1] | |
| Pancreatic cancer [ICD-11: 2C10; ICD-9: 157] | Phase 2 | [2] | ||
| Epidermolysis bullosa [ICD-11: EC3Z] | Phase 1 | [3] | ||
| Company |
Berg Framingham, MA
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04752813) A Study of BPM31510 With Vitamin K1 in Subjects With Newly Diagnosed Glioblastoma (GB). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02650804) A Phase 2 Study of BPM31510 (Ubidecarenone, USP) Nanosuspension Injection Administered Intravenously With Gemcitabine as 2nd/3rdline Therapy in Advanced Pancreatic Cancer Patients. U.S.National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT02793960) Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.